Keyur Patel1, Sumeet K Asrani2, Maria Isabel Fiel3, Deborah Levine4, Daniel H. Leung5,
Andres Duarte-Rojo6, Jonathan A. Dranoff7 Page 1 Accuracy of blood-based biomarkers for …

Liver biopsy is historically the gold standard for liver fibrosis assessment of chronic hepatitis
C patients. However, with the introduction and validation of noninvasive tests (NITs) to …

Objective The aim of this study was to evaluate the applicability of phase angle (PhA) as a
severity indicator of chronic liver diseases. Methods We examined the medical records of 54 …

Method: It is a cross-sectional study that was conducted in a tertiary health care center in
Uttar Pradesh, India, from January 2017 to January 2020. Fibroscan was done for all …

Background Liver biopsy is the criterion standard for diagnosing liver fibrosis, but it is not
widely used to monitor liver fibrosis because of the invasiveness, risk of complications, and …

Background Thrombocytopenia is a common extrahepatic manifestation in chronic liver
disease. However, there have been rare studies of impacts of risk for hepatitis C virus …

Objectives The aim of this study was to compare the correlation of gamma‐glutamyl
transpeptidase‐to‐platelet ratio (GPR), aspartate aminotransferase‐to‐platelet ratio index …

Results Twenty-six patients (24.52%) had F4 fibrosis, 80 patients (75.48%) had non-F4
fibrosis (F0-F3). There was a statistically significant difference (p< 0.05) between non-F4 …

BACKGROUND: A rapid decline of liver stiffness (LS) was detected by non-invasive
methods in patients with chronic hepatitis C (HCV) infection during treatment with direct …

More than five years ago, the treatment of hepatitis C virus infection was revolutionized with
the introduction of all-oral direct-acting antiviral (DAA) drugs. They proved highly efficient in …